-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the State Food and Drug Administration showed that Anhui Hengxing Pharmaceutical entered the administrative approval stage by imitating Class 3 levofloxacin injection
.
At present, 3 companies for levofloxacin injection have been approved, which has been affected by the generic drug market
.
.
At present, 3 companies for levofloxacin injection have been approved, which has been affected by the generic drug market
.
Source: State Food and Drug Administration official website
Levofloxacin is a quinolone antibiotic, suitable for respiratory system infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
.
The dosage forms of levofloxacin include tablets, capsules, injections, solutions, ointments, gels, and ophthalmic preparations
.
In 2002, the levofloxacin injection of Daiichi Sankyo Pharmaceutical was launched in China
.
.
The dosage forms of levofloxacin include tablets, capsules, injections, solutions, ointments, gels, and ophthalmic preparations
.
In 2002, the levofloxacin injection of Daiichi Sankyo Pharmaceutical was launched in China
.
According to data from Minet.
com, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4 billion yuan; the first half of 2021 increased by 4.
58% year-on-year .
Among them, the market share of Yangzijiang Pharmaceutical is close to 30%
.
com, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4 billion yuan; the first half of 2021 increased by 4.
58% year-on-year .
Among them, the market share of Yangzijiang Pharmaceutical is close to 30%
.
Sales of terminal levofloxacin injection in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, three companies have been approved for production of levofloxacin injection, including Yangzijiang, Zhitong Bio and Fuan Pharmaceutical, of which Yangzijiang is the first to have reviewed it
.
In addition to Anhui Xingxing, there are more than 5 levofloxacin injection manufacturers, including Hualu, Sihuan, Qidu, Zhengke,
etc.
.
In addition to Anhui Xingxing, there are more than 5 levofloxacin injection manufacturers, including Hualu, Sihuan, Qidu, Zhengke,
etc.
In February and June 2021, levofloxacin tablets and levofloxacin sodium chloride injection were included in the fourth and fifth batches of collection, respectively
.
The products of Haihui, Zhejiang Medicine , Kelun, Qidu and other related companies have all won the bids at low prices
.
.
The products of Haihui, Zhejiang Medicine , Kelun, Qidu and other related companies have all won the bids at low prices
.
Like many original products developed by foreign companies, Daiichi Sankyo Pharma actively chose out of the market by quoting high prices in these two centralized procurements
.
Affected by the centralized procurement, the levofloxacin market of Daiichi Sankyo Pharmaceutical Co.
, Ltd.
has been looted by many domestic generic drugs.
The company recently announced that it will transfer the production and sales rights of levofloxacin tablets and levofloxacin injection in mainland China to Fosun Pharma, involving both parties.
not disclosed
.
.
Affected by the centralized procurement, the levofloxacin market of Daiichi Sankyo Pharmaceutical Co.
, Ltd.
has been looted by many domestic generic drugs.
The company recently announced that it will transfer the production and sales rights of levofloxacin tablets and levofloxacin injection in mainland China to Fosun Pharma, involving both parties.
not disclosed
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of April 8.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Recently, the official website of the State Food and Drug Administration showed that Anhui Hengxing Pharmaceutical entered the administrative approval stage by imitating Class 3 levofloxacin injection
.
At present, 3 companies for levofloxacin injection have been approved, which has been affected by the generic drug market
.
.
At present, 3 companies for levofloxacin injection have been approved, which has been affected by the generic drug market
.
Source: State Food and Drug Administration official website
Levofloxacin is a quinolone antibiotic, suitable for respiratory system infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
.
The dosage forms of levofloxacin include tablets, capsules, injections, solutions, ointments, gels, and ophthalmic preparations
.
In 2002, the levofloxacin injection of Daiichi Sankyo Pharmaceutical was launched in China
.
.
The dosage forms of levofloxacin include tablets, capsules, injections, solutions, ointments, gels, and ophthalmic preparations
.
In 2002, the levofloxacin injection of Daiichi Sankyo Pharmaceutical was launched in China
.
According to data from Minet.
com, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4 billion yuan; the first half of 2021 increased by 4.
58% year-on-year .
Among them, the market share of Yangzijiang Pharmaceutical is close to 30%
.
com, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4 billion yuan; the first half of 2021 increased by 4.
58% year-on-year .
Among them, the market share of Yangzijiang Pharmaceutical is close to 30%
.
Sales of terminal levofloxacin injection in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, three companies have been approved for production of levofloxacin injection, including Yangzijiang, Zhitong Bio and Fuan Pharmaceutical, of which Yangzijiang is the first to have reviewed it
.
In addition to Anhui Xingxing, there are more than 5 levofloxacin injection manufacturers, including Hualu, Sihuan, Qidu, Zhengke,
etc.
.
In addition to Anhui Xingxing, there are more than 5 levofloxacin injection manufacturers, including Hualu, Sihuan, Qidu, Zhengke,
etc.
In February and June 2021, levofloxacin tablets and levofloxacin sodium chloride injection were included in the fourth and fifth batches of collection, respectively
.
The products of Haihui, Zhejiang Medicine , Kelun, Qidu and other related companies have all won the bids at low prices
.
.
The products of Haihui, Zhejiang Medicine , Kelun, Qidu and other related companies have all won the bids at low prices
.
Like many original products developed by foreign companies, Daiichi Sankyo Pharma actively chose out of the market by quoting high prices in these two centralized procurements
.
Affected by the centralized procurement, the levofloxacin market of Daiichi Sankyo Pharmaceutical Co.
, Ltd.
has been looted by many domestic generic drugs.
The company recently announced that it will transfer the production and sales rights of levofloxacin tablets and levofloxacin injection in mainland China to Fosun Pharma, involving both parties.
not disclosed
.
.
Affected by the centralized procurement, the levofloxacin market of Daiichi Sankyo Pharmaceutical Co.
, Ltd.
has been looted by many domestic generic drugs.
The company recently announced that it will transfer the production and sales rights of levofloxacin tablets and levofloxacin injection in mainland China to Fosun Pharma, involving both parties.
not disclosed
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of April 8.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
Recently, the official website of the State Food and Drug Administration showed that Anhui Hengxing Pharmaceutical entered the administrative approval stage by imitating Class 3 levofloxacin injection
.
At present, 3 companies for levofloxacin injection have been approved, which has been affected by the generic drug market
.
.
At present, 3 companies for levofloxacin injection have been approved, which has been affected by the generic drug market
.
Source: State Food and Drug Administration official website
Levofloxacin is a quinolone antibiotic, suitable for respiratory system infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
.
The dosage forms of levofloxacin include tablets, capsules, injections, solutions, ointments, gels, and ophthalmic preparations
.
In 2002, the levofloxacin injection of Daiichi Sankyo Pharmaceutical was launched in China
.
.
The dosage forms of levofloxacin include tablets, capsules, injections, solutions, ointments, gels, and ophthalmic preparations
.
In 2002, the levofloxacin injection of Daiichi Sankyo Pharmaceutical was launched in China
.
According to data from Minet.
com, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4 billion yuan; the first half of 2021 increased by 4.
58% year-on-year .
Among them, the market share of Yangzijiang Pharmaceutical is close to 30%
.
hospital hospital hospitalcom, in 2020, the sales of terminal levofloxacin injection in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 4 billion yuan; the first half of 2021 increased by 4.
58% year-on-year .
Among them, the market share of Yangzijiang Pharmaceutical is close to 30%
.
Sales of terminal levofloxacin injection in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
At present, three companies have been approved for production of levofloxacin injection, including Yangzijiang, Zhitong Bio and Fuan Pharmaceutical, of which Yangzijiang is the first to have reviewed it
.
In addition to Anhui Xingxing, there are more than 5 levofloxacin injection manufacturers, including Hualu, Sihuan, Qidu, Zhengke,
etc.
.
In addition to Anhui Xingxing, there are more than 5 levofloxacin injection manufacturers, including Hualu, Sihuan, Qidu, Zhengke,
etc.
In February and June 2021, levofloxacin tablets and levofloxacin sodium chloride injection were included in the fourth and fifth batches of collection, respectively
.
The products of Haihui, Zhejiang Medicine , Kelun, Qidu and other related companies have all won the bids at low prices
.
Pharmaceutical pharmaceutical pharmaceutical enterprise enterprise enterprise.
The products of Haihui, Zhejiang Medicine , Kelun, Qidu and other related companies have all won the bids at low prices
.
Like many original products developed by foreign companies, Daiichi Sankyo Pharma actively chose out of the market by quoting high prices in these two centralized procurements
.
Affected by the centralized procurement, the levofloxacin market of Daiichi Sankyo Pharmaceutical Co.
, Ltd.
has been looted by many domestic generic drugs.
The company recently announced that it will transfer the production and sales rights of levofloxacin tablets and levofloxacin injection in mainland China to Fosun Pharma, involving both parties.
not disclosed
.
.
Affected by the centralized procurement, the levofloxacin market of Daiichi Sankyo Pharmaceutical Co.
, Ltd.
has been looted by many domestic generic drugs.
The company recently announced that it will transfer the production and sales rights of levofloxacin tablets and levofloxacin injection in mainland China to Fosun Pharma, involving both parties.
not disclosed
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Source: Minet database, the official website of the State Food and Drug Administration, etc. Note: The statistics are as of April 8.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
